Amphastar Pharmaceuticals (AMPH) Capital Expenditures (2013 - 2026)

Amphastar Pharmaceuticals' Capital Expenditures history runs 14 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 42.17% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $4.7 million (down 88.1% YoY), while the FY2025 annual figure was $7.7 million, down 81.14% from the prior year.
• Capital Expenditures was $4.2 million for Q1 2026 at Amphastar Pharmaceuticals, up from -$18.9 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $21.9 million in Q3 2024 to a low of -$18.9 million in Q4 2025.
• Historically, Capital Expenditures has averaged $5.7 million across 5 years, with a median of $7.2 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Capital Expenditures soared 1646.32% in 2022, then slumped 252.03% in 2025.
• A 5-year view of Capital Expenditures shows it stood at -$12.5 million in 2022, then soared by 175.73% to $9.4 million in 2023, then jumped by 31.44% to $12.4 million in 2024, then plunged by 252.03% to -$18.9 million in 2025, then surged by 122.12% to $4.2 million in 2026.
• The last three Capital Expenditures figures came in at $4.2 million (Q1 2026), -$18.9 million (Q4 2025), and $20.6 million (Q3 2025), per Business Quant data.